Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

7,893 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A retrospective comparison of allogenic and autologous chimeric antigen receptor T cell therapy targeting CD19 in patients with relapsed/refractory acute lymphoblastic leukemia.
Hu Y, Wang J, Wei G, Yu J, Luo Y, Shi J, Wu W, Zhao K, Xiao L, Zhang Y, Wu Z, Xu H, Chang AH, Huang H. Hu Y, et al. Among authors: zhao k. Bone Marrow Transplant. 2019 Aug;54(8):1208-1217. doi: 10.1038/s41409-018-0403-2. Epub 2018 Dec 5. Bone Marrow Transplant. 2019. PMID: 30518980
Role of Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Predicting the Adverse Effects of Chimeric Antigen Receptor T Cell Therapy in Patients with Non-Hodgkin Lymphoma.
Wang J, Hu Y, Yang S, Wei G, Zhao X, Wu W, Zhang Y, Zhang Y, Chen D, Wu Z, Xiao L, Chang AH, Huang H, Zhao K. Wang J, et al. Among authors: zhao k, zhao x. Biol Blood Marrow Transplant. 2019 Jun;25(6):1092-1098. doi: 10.1016/j.bbmt.2019.02.008. Epub 2019 Feb 12. Biol Blood Marrow Transplant. 2019. PMID: 30769193 Free article.
Tumor Burden Measured by 18F-FDG PET/CT in Predicting Efficacy and Adverse Effects of Chimeric Antigen Receptor T-Cell Therapy in Non-Hodgkin Lymphoma.
Hong R, Tan Su Yin E, Wang L, Zhao X, Zhou L, Wang G, Zhang M, Zhao H, Wei G, Wang Y, Wu W, Zhang Y, Ni F, Hu Y, Huang H, Zhao K. Hong R, et al. Among authors: zhao k, zhao x, zhao h. Front Oncol. 2021 Aug 4;11:713577. doi: 10.3389/fonc.2021.713577. eCollection 2021. Front Oncol. 2021. PMID: 34422666 Free PMC article.
Efficacy and safety of neoadjuvant sintilimab, oxaliplatin and capecitabine in patients with locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: early results of a phase 2 study.
Jiang H, Yu X, Li N, Kong M, Ma Z, Zhou D, Wang W, Wang H, Wang H, He K, Li Z, Lu Y, Zhang J, Zhao K, Zhang Y, Xu N, Li Z, Liu Y, Wang Y, Wang Y, Teng L. Jiang H, et al. Among authors: zhao k. J Immunother Cancer. 2022 Mar;10(3):e003635. doi: 10.1136/jitc-2021-003635. J Immunother Cancer. 2022. PMID: 35296556 Free PMC article. Clinical Trial.
7,893 results